Courtagen Life Sciences, Inc. To Provide Genetic Profiling Of Children With Intractable Epilepsy To Support Clinical Developments With Cannabidiol
4/2/2014 8:44:10 AM
WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences, an innovative molecular information company, announces a new comprehensive epilepsy sequencing test designed to sequence 489 genes known to be involved in epilepsy, antiepileptic drug metabolism, and endocannabinoid regulation. This panel is to be the first deployed in the genetic analysis of over 100 children suffering from intractable epilepsy syndromes.
Help employers find you! Check out all the jobs and post your resume.
comments powered by